Speciality: Pediatrics
Description:
A warm welcome to all the medical professionals in this interesting session of evolution of vaccination. We have Dr Srivastava and Dr Jaydeep Choudhury to lead the session.
It is well known to each one of us how the science of vaccine development has evolved starting from the invention of attenuated vaccines. We are also aware about the importance of vaccination for the children or neonates.
In this webinar, a more detailed discussion is provided on the development of 6-in-1 aP combination vaccine, its usage and its importance among the pediatric population.
The 6-in-1 aP combination vaccine is referred as DTaP/Hib/HepB/IPV, stands for 'Diphtheria, Tetanus, acellular Pertussis, Hib, Hepatitis B and Inactivated Polio Vaccine'. The advantage is one single vaccine can protect the child from the mentioned diseases and save the child from taking each of vaccines separately.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
See More Webinars @ Hidoc Webinars
1.
While most cancer screenings won't prolong lives, there are still good reasons to continue screening.
2.
High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?
3.
Cancer Diagnoses Slow to Recover From Effects of COVID Pandemic
4.
The pandemic had little impact on mental health symptoms.
5.
How breast tissue density affects your risk of breast cancer
1.
Uncovering Breast Cancer: The Power of Early Stage Ultrasound
2.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
3.
The Miracle of Tenecteplase: How This Drug Is Saving Lives
4.
Cancer-Keeper Genes: Novel Therapeutic Targets for Disrupting Tumor Maintenance
5.
Patient-Centric Approaches in Hematology: Integrating Individualized Care into Modern Clinical Practice
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
2.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation